Abstract: The invention relates to a method of manufacture of fast-disintegrating solid dosage forms, characterized in that one or more structure building components in mixed solid powder form are dosed into cavities of blister packs or moulds, the remaining components dissolved in water dosed and added to the powder to form a moistened, plasticized mass, frozen to below ?20° C., and the water sublimed in high vacuum. In this way solid dosage forms are obtained with a similar porous structure as usually result from freeze drying processes, but the process requires much less water, which means considerably less time and less energy.

Abstract: The invention relates to a method of manufacture of fast-disintegrating solid dosage forms, characterized in that one or more structure building components in mixed solid powder form are dosed into cavities of blister packs or moulds, the remaining components dissolved in water dosed and added to the powder to form a moistened, plasticized mass, frozen to below ?20° C. , and the water sublimed in high vacuum. In this way solid dosage forms are obtainable with a similar porous structure as usually result from freeze-drying processes, but the process requires much less water, which means considerably less time and less energy.

Abstract: The invention relates to the use of copolymers comprising a) 82 to 99.9 mol % of at least one monoethylenically unsaturated C3-C8-carboxylic acid; b) 0.1 to 18 mol % of at least one monomer selected from the group b1) N—C8-C30-alkyl-substituted amides of monoethylenically unsaturated C3-C8-carboxylic acids, b2) N,N—C8-C30-dialkyl-substituted amides of monoethylenically unsaturated C3-C8-carboxylic acids, b3) C8-C30-alkyl esters of monoethylenically unsaturated C3-C8-carboxylic acids; c) 0 to 17.9 mol % of at least one monomer selected from the group of c1) vinyl esters of aliphatic C8-C30-carboxylic acids, c2) C8-C30-alkylvinyl ethers, the mol % data for the individual components adding up to 100%, as solubilizer.

Abstract: The invention relates to the use of copolymers comprising

Abstract: The invention relates to the use of copolymers comprising a) 82 to 99.9 mol % of at least one monoethylenically unsaturated C3-C8-carboxylic acid; b) 0.1 to 18 mol % of at least one monomer selected from the group b1) N—C8-C30-alkyl-substituted amides of monoethylenically unsaturated C3-C8-carboxylic acids, b2) N,N—C8-C30-dialkyl-substituted amides of monoethylenically unsaturated C3-C8-carboxylic acids, b3) C8-C30-alkyl esters of monoethylenically unsaturated C3-C8-carboxylic acids; c) 0 to 17.9 mol % of at least one monomer selected from the group of c1) vinyl esters of aliphatic C8-C30-carboxylic acids, c2) C8-C30-alkylvinyl ethers, mol % data for the individual components adding up to 100%, as solubilizer.

Abstract: Dextran esters with a molecular weight of 10,000-10,000,000 and ester side chains which are derived from acids with 6-18 carbon atoms, where the degree of esterification is adjusted, depending on the number of carbon atoms in the side chains and the molecular weight, to a value of 0.04-1.1 so that the dextran esters are insoluble in water at room temperature and are broken down by colonic bacteria, and their use for coating and/or embedding pharmaceutical active ingredients or drug formulations.

Abstract: The invention relates to polysaccharides which are crosslinked with bifunctional crosslinkers and are no longer water-soluble but are still biodegradable, have a swelling of from 100 to 1000%, where the swelling, which means the percentage gain in weight, is determined by the following equation: ##EQU1## in which A is the percentage gain in weight, W.sub.o is the weight of the dry polymer and W.sub.t is the weight of the swollen polymer saturated with water. It likewise relates to a process for preparing the crosslinked polysaccharides and to the use of the crosslinked polysaccharides for coating and/or embedding medicinal active substances or drug compositions. The invention furthermore relates to a drug which contains an active substance which acts in the large intestine or an active substance which is broken down on passing through the stomach or small intestine, coated with or embedded in one of the crosslinked polysaccharides.

Abstract: Liquid, active substance formulations containing an active substance insoluble or poorly soluble in water, or a mixture, a phospholipid, a special co-emulsifier (glycerinester in which the 1 or 2 OH groups have been esterized with hydrocarbon atoms of 8-16, preferably 8-10, C atoms by means of fatty acids and the 3 or remaining OH group of the glycerin body has been etherized with polyethyleneglycol, specifically, with 6-30, preferably 6-15 ethyleneoxide units) and a liquid carrier, the molar ratio of phospholipid to co-emulsifier being from 1:1 to 1:4, and the formulations being such that when added to water they form a transparent liquid system in the form of a microemulsion, with a degree of fineness of 10-200 nm in the lipid phase.